Petah Tikva, Israel, April 08, 2018 – Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer, confirm to be ready for their long-term strategy.
In the study, conducted at the Catholic University of Leuven, Belgium under the supervision of Professor Bart Meyns, MD, Ph.D. the technology has demonstrated efficiency, tolerance and stability with repeated 8 hours of discharge and recharge of an internal battery powered MCS device for more than 60 days.
Michael Zilbershlag, BSc, MBA, CEO of Leviticus Cardio comments, “This is the first step of an ambitious strategy. Our goal is to offer a versatile wireless energy transfer to ALL patients requiring long term MCS support. Many key international opinion leaders have already expressed their willingness to support us and demonstrate the possibility of our CET technology.” states Mr Zilbershlag.
Stephan Schueler, M.D., Ph.D Newcastle upon Tyne, Freeman Hospital, UK commented “The successful completion of the animal trials with the wireless Coplanar Energy Transfer (CET) opens a new era for long term LVAD implants”. Professor Jiri Maly, MD, Ph.D., from IKEM stated that “based on our current experience, the CET system is easy to implant and doesn’t increase the complexity of surgery compared to a standard LVAD procedure”.
CALENDAR INFO
Leviticus will participate to ISHLT 2018 (International Society for Heart & Lung Transplantation) meeting at The Acropolis Congress Centre, Nice, France. April 11th -13th, 2018 VAD update session.
For one/one meeting during the congress please send a request at: “info@leviticus-cardio.com”
About Leviticus Cardio
Leviticus Cardio (Leviticus-cardio.com) is a medical device company founded in 2008 dedicated to improve the clinical outcome for patients implanted with a left ventricular assist device (LVAD) for impaired cardiac function. Major investors include The Trendlines Group, Israel’s foremost seed- and early-stage investment group, a consortium of acclaimed cardiovascular physicians, private investors and Israel’s Office of the Chief Scientist (OCS) in the Ministry of Economy.
Glenn Kenworthy 